Objectives: To assess clinical and sonographic findings and cancer risk of patients with non-atypical endometrial hyperplasia (NEH) in women with postmenopausal bleeding. Methods: A retrospective analysis of women, age 55 and older, who underwent endometrial sampling between 1997 and 2008. The study group included patients with current or prior confirmed diagnosis of NEH. The women were followed through 2015 for long term clinical outcome. Clinical and sonographic data was analysed and compared between the study group and all other cases with benign endometrial pathology. P<0.05 was considered statistically significant. Results: 1808 women were included in the study with mean age of 64.5 (55 to 96 years). Mean surveillance time was 11.0+/-2.7 years (range: 6.3-17.8). Pathology breakdown showed: 123 (6.8%) cases of endometrial cancer, 20 (1.1%) complex atypical hyperplasia and 73 (4.0%) NEH (51 of the cases were newly diagnosed and 22 had a prior diagnosis of NEH). 26/73(35.6%) had non-atypical complex hyperplasia (NCH) and 47 (64.4%) had simple hyperplasia (SH). Women with NEH had similar age and significantly higher BMI compared to the rest of the patients (63.4% vs. 64.2% p=0.85 and 33.9 vs. 31.4, P=0.01 respectively). On ultrasound, the mean endometrial thickness (EE) of the study group was 11.1mm (1-30mm). 5 women had EE < 5mm but none of them developed cancer.
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Risk of endometrial cancer in asymptomatic postmenopausal women with endometrial thickness >11mm: systematic review and meta-analysis Objectives: To evaluate the risk of endometrial cancer (EC) and/or endometrial hyperplasia with atypia (EHA) in asymptomatic postmenopausal women with endometrial thickness ≥11mm. Methods: Systematic review of literature using database search (Pubmed, Web of Science and Google Scholar) of articles published between January 2000 and December 2016 evaluating the correlation between endometrial thickness as measured by transvaginal ultrasound(double layer) and histopathological findings in asymptomatic postmenopausal women, using the following terms: ''endometrial thickness", ''postmenopausal", ''postmenopause" and ''asymptomatic". Inclusion criteria were prospective or retrospective studies of more than 150 cases that provided information on endometrial thickness and its correlation with histopathological data. Studies that included patients with hormone replacement therapy, tamoxifen, SERMs and/or aromatase inhibitors were excluded. The overall relative risk (RR) for EC/EHA was calculated, stratifying the patients into two groups according to endometrial thickness (<11mm and ≥11mm). Heterogeneity was assessed by calculating I 2 .
Results:
The search identified 503 studies. After reading title and abstract, 462 articles were discarded. Full text of 41 articles was reviewed, of which 33 were discarded and 8 articles that met all the inclusion criteria were finally selected for evaluation. A total of 4382 women were included. The prevalence of EC/HEA was 0.03% (72 cases). The relative risk of EC/EHA in the ≥11mm group was 3.1 (95% CI: 1.5-6.4). Moderate heterogeneity was observed between studies (I2: 44.6%, p = 0.08).
Conclusions:
The risk of EC/HEA in asymptomatic postmenopausal women with endometrial thickness ≥11mm is three times greater than in women with endometrial thickness <11mm. The indication of endometrial biopsy in these cases seems justifiable.
OC17.04
Intra-and interobserver agreement using the MUSA terminology for ultrasonographic features associated with ill-defined lesions 
